E
Whitehawk Therapeutics, Inc.
WHWK
$1.64
$0.021.24%
E
Sell
4/2/2025Downgrade
Whitehawk Therapeutics, Inc. (WHWK) was downgraded to E+ from D- on 4/2/2025 due to a large decline in the growth index, volatility index and solvency index. EBIT declined 75.86% from -$10.78M to -$18.95M, earnings per share declined from -$0.464 to -$0.6746, and the quick ratio declined from 4.37 to 3.11.
Whitehawk Therapeutics, Inc. (WHWK) was downgraded to E+ from D- on 4/2/2025 due to a large decline in the growth index, volatility index and solvency index. EBIT declined 75.86% from -$10.78M to -$18.95M, earnings per share declined from -$0.464 to -$0.6746, and the quick ratio declined from 4.37 to 3.11.
D
Sell
3/20/2025Upgraded
Whitehawk Therapeutics, Inc. (WHWK) was upgraded to D- from E+ on 3/20/2025 due to an increase in the volatility index and total return index.
Whitehawk Therapeutics, Inc. (WHWK) was upgraded to D- from E+ on 3/20/2025 due to an increase in the volatility index and total return index.
E
Sell
2/28/2025Downgrade
Aadi Bioscience, Inc. (AADI) was downgraded to E+ from D- on 2/28/2025 due to a decline in the volatility index.
Aadi Bioscience, Inc. (AADI) was downgraded to E+ from D- on 2/28/2025 due to a decline in the volatility index.
D
Sell
2/11/2025Upgraded
Aadi Bioscience, Inc. (AADI) was upgraded to D- from E+ on 2/11/2025 due to an increase in the volatility index and total return index.
Aadi Bioscience, Inc. (AADI) was upgraded to D- from E+ on 2/11/2025 due to an increase in the volatility index and total return index.
E
Sell
1/23/2025Downgrade
Aadi Bioscience, Inc. (AADI) was downgraded to E+ from D- on 1/23/2025 due to a decline in the volatility index.
Aadi Bioscience, Inc. (AADI) was downgraded to E+ from D- on 1/23/2025 due to a decline in the volatility index.
D
Sell
1/6/2025Upgraded
Aadi Bioscience, Inc. (AADI) was upgraded to D- from E+ on 1/6/2025 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 30.86% from -$15.58M to -$10.78M, total revenue increased 16.72% from $6.18M to $7.21M, and earnings per share increased from -$0.5399 to -$0.464.
Aadi Bioscience, Inc. (AADI) was upgraded to D- from E+ on 1/6/2025 due to a noticeable increase in the growth index, volatility index and total return index. EBIT increased 30.86% from -$15.58M to -$10.78M, total revenue increased 16.72% from $6.18M to $7.21M, and earnings per share increased from -$0.5399 to -$0.464.
E
Sell
7/22/2024Upgraded
Aadi Bioscience, Inc. (AADI) was upgraded to E+ from E on 7/22/2024 due to an increase in the volatility index.
Aadi Bioscience, Inc. (AADI) was upgraded to E+ from E on 7/22/2024 due to an increase in the volatility index.
E
Sell
7/5/2024Downgrade
Aadi Bioscience, Inc. (AADI) was downgraded to E from E+ on 7/5/2024 due to a major decline in the solvency index, total return index and volatility index.
Aadi Bioscience, Inc. (AADI) was downgraded to E from E+ on 7/5/2024 due to a major decline in the solvency index, total return index and volatility index.
E
Sell
3/14/2023Downgrade
Aadi Bioscience, Inc. (AADI) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index and volatility index.
Aadi Bioscience, Inc. (AADI) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index and volatility index.
D
Sell
3/3/2023Downgrade
Aadi Bioscience, Inc. (AADI) was downgraded to D- from D on 3/3/2023 due to a decline in the volatility index and total return index.
Aadi Bioscience, Inc. (AADI) was downgraded to D- from D on 3/3/2023 due to a decline in the volatility index and total return index.
D
Sell
2/9/2023Upgraded
Whitehawk Therapeutics, Inc. (WHWK) was upgraded to D from E+ on 02/09/2023.
Whitehawk Therapeutics, Inc. (WHWK) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Aadi Bioscience, Inc. (AADI) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index.
Aadi Bioscience, Inc. (AADI) was downgraded to E+ from D on 2/8/2023 due to a decline in the total return index.
D
Sell
12/16/2022Upgraded
Aadi Bioscience, Inc. (AADI) was upgraded to D from D- on 12/16/2022 due to an increase in the volatility index and total return index.
Aadi Bioscience, Inc. (AADI) was upgraded to D from D- on 12/16/2022 due to an increase in the volatility index and total return index.
D
Sell
12/1/2022Downgrade
Aadi Bioscience, Inc. (AADI) was downgraded to D- from D on 12/1/2022 due to a decline in the volatility index.
Aadi Bioscience, Inc. (AADI) was downgraded to D- from D on 12/1/2022 due to a decline in the volatility index.
D
Sell
11/11/2022Upgraded
Aadi Bioscience, Inc. (AADI) was upgraded to D from D- on 11/11/2022 due to a substantial increase in the growth index. Operating cash flow increased 23.55% from -$10.72M to -$8.2M, total revenue increased 23.51% from $3.44M to $4.25M, and earnings per share increased from -$0.8712 to -$0.6805.
Aadi Bioscience, Inc. (AADI) was upgraded to D from D- on 11/11/2022 due to a substantial increase in the growth index. Operating cash flow increased 23.55% from -$10.72M to -$8.2M, total revenue increased 23.51% from $3.44M to $4.25M, and earnings per share increased from -$0.8712 to -$0.6805.
D
Sell
5/2/2022Upgraded
Aadi Bioscience, Inc. (AADI) was upgraded to D- from E+ on 5/2/2022 due to an increase in the volatility index.
Aadi Bioscience, Inc. (AADI) was upgraded to D- from E+ on 5/2/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Upgraded
Aadi Bioscience, Inc. (AADI) was upgraded to E+ from E on 5/1/2022 due to a large increase in the solvency index and growth index. Earnings per share increased from -$9.1733 to -$0.7654, and operating cash flow increased 28.46% from -$17.37M to -$12.43M.
Aadi Bioscience, Inc. (AADI) was upgraded to E+ from E on 5/1/2022 due to a large increase in the solvency index and growth index. Earnings per share increased from -$9.1733 to -$0.7654, and operating cash flow increased 28.46% from -$17.37M to -$12.43M.
E
Sell
2/1/2022Upgraded
Aadi Bioscience, Inc. (AADI) was upgraded to E from E- on 2/1/2022 due to an increase in the valuation index.
Aadi Bioscience, Inc. (AADI) was upgraded to E from E- on 2/1/2022 due to an increase in the valuation index.
E
Sell
12/30/2021Downgrade
Aadi Bioscience, Inc. (AADI) was downgraded to E- from E on 12/30/2021 due to a decline in the total return index, volatility index and valuation index.
Aadi Bioscience, Inc. (AADI) was downgraded to E- from E on 12/30/2021 due to a decline in the total return index, volatility index and valuation index.
E
Sell
12/15/2021Upgraded
Aadi Bioscience, Inc. (AADI) was upgraded to E from E- on 12/15/2021 due to a noticeable increase in the total return index, volatility index and valuation index.
Aadi Bioscience, Inc. (AADI) was upgraded to E from E- on 12/15/2021 due to a noticeable increase in the total return index, volatility index and valuation index.
E
Sell
11/24/2021Downgrade
Aadi Bioscience, Inc. (AADI) was downgraded to E- from E on 11/24/2021 due to a decline in the volatility index.
Aadi Bioscience, Inc. (AADI) was downgraded to E- from E on 11/24/2021 due to a decline in the volatility index.
E
Sell
11/19/2021None
Whitehawk Therapeutics, Inc. (WHWK) was downgraded to E from U on 11/19/2021.
Whitehawk Therapeutics, Inc. (WHWK) was downgraded to E from U on 11/19/2021.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
